Table 1. List of candidate compounds identified by high throughput drug screening [1].
| FDA approved agents (N=23) | Target/class |
|---|---|
| GSK1070916 | Aurora Kinase |
| PF-03814735 | Aurora Kinase |
| CYC116 | Aurora Kinase |
| CO-1686 (AVL-301) | EGFR |
| OSI-420 | EGFR |
| Erlotinib HCl | EGFR |
| PD173074 | FGFR |
| TAK-632 | Raf |
| Bosutinib (SKI-606) | Src |
| TW-37 | Bcl-2 |
| KPT-276 | CRM1 |
| CNX-774 | BTK |
| Thioguanosine | Purine metabolism |
| HMN-214 | PLK |
| CX-4945 (Silmitasertib) | CK2 |
| PTC-209 | BMI-1 |
| Ispinesib (SB-715992) | Kinesin |
| Oprozomib (ONX 0912) | Proteasome |
| BX-795 | IκB/IKK |
| Tipifarnib (Zarnestra) | Transferase |
| Rilpivirine | Reverse Transcriptase |
| Ciclopirox (Penlac) | Antifungal agent |
| Raloxifene HCl | Estrogen agonist/antagonist |
EGFR, epidermal growth factor receptor; FGFR, fibroblast growth factor receptor; CRM1, chromosome maintenance protein 1; BTK, Bruton’s tyrosine kinase; PLK, polo-like kinase; CK2, Casein kinase 2; BMI-1, B lymphoma Mo-MLV insertion region 1.